Zacks issues Update on Access Pharma Report

Great news for Access Pharmaceuticals, who have just released MuGard, a revolutionary prescription strength, mouth wash rinse for chemotherapy patients who develop oral mucositis as a result of the treatment. It is Access' hope that patients will use MuGard to remedy any cases of mucositis, in order to continue treatment moving toward a favorable outcome.

"Grand Zeng of Zacks Research issued an update yesterday on their "Outperform" rating on Access Pharmaceuticals (OTCBB: ACCP) with a six month price target of $8.00. ACCP is trading today at $1.95.

Zacks Equity Research combines quantitative models with the insight provided by experienced equity analysts to create superior long-term stock recommendations.

Access Pharmaceuticals, Inc. (OTCBB: ACCP) is an emerging bio-pharmaceutical company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to a treatment called MuGard that is cleared for marketing in the U.S., Europe, and other key global markets for a common side effect of some cancer treatments known as mucositis (painful sores in the mouth and GI mucosal lining)."

http://www.proactivenewsroom.com/access-pharma-blog/bid/50024/Zacks-Issues-Update-on-their-Outperform-Research-Report-on-Access-Pharmaceuticals-OTCBB-ACCP